V Weingärtner1, N Dargatz1, C Weber2, D Mueller2, S Stock2, R Voltz1, J Gaertner1,3,4. 1. a Department of Palliative Medicine, Clinical Trials Unit and Center for Integrated Oncology (CIO) Cologne/Bonn , University Hospital of Cologne , Cologne , Germany. 2. b Institute of Health Economics and Clinical Epidemiology (IGKE) , University Hospital of Cologne , Cologne , Germany. 3. c Department of Palliative Care , University Hospital Freiburg , Freiburg , Germany. 4. d Competence Center Palliative Care Baden-Württemberg , University Medical Center Freiburg , Freiburg , Baden-Württemberg , Germany.
Abstract
INTRODUCTION: In advanced cancer quality of life (QoL) is the most important goal of care. It is measured by patient-reported-outcomes (PRO). This structured review evaluated how randomized controlled trials (RCTs) on anti-cancer therapy in advanced cancer reported PRO. METHODS: Search was performed in MEDLINE via PubMed for RCTs with median patient survival of ≤2 years. Reporting was rated with the Consolidated Standards of Reporting Trials (CONSORT) PRO extension. RESULTS: Of 370 retrieved publications, 117 were eligible, but only 30/117 (26%) reported PRO. QoL was most frequently measured (29/30). On average, 4.4 (SD 2.5) of the 14 CONSORT items were met. CONCLUSION: PRO are insufficiently reported in advanced cancer trials. Yet, this is paramount to enable an informed and patient-oriented decision making process.
INTRODUCTION: In advanced cancer quality of life (QoL) is the most important goal of care. It is measured by patient-reported-outcomes (PRO). This structured review evaluated how randomized controlled trials (RCTs) on anti-cancer therapy in advanced cancer reported PRO. METHODS: Search was performed in MEDLINE via PubMed for RCTs with median patient survival of ≤2 years. Reporting was rated with the Consolidated Standards of Reporting Trials (CONSORT) PRO extension. RESULTS: Of 370 retrieved publications, 117 were eligible, but only 30/117 (26%) reported PRO. QoL was most frequently measured (29/30). On average, 4.4 (SD 2.5) of the 14 CONSORT items were met. CONCLUSION: PRO are insufficiently reported in advanced cancer trials. Yet, this is paramount to enable an informed and patient-oriented decision making process.
Entities:
Keywords:
Quality of life; advanced cancer; decision-making; early integration; early palliative care; oncology; palliative care
Authors: Rebecca Mercieca-Bebber; Julie Rouette; Melanie Calvert; Madeleine T King; Lori McLeod; Patricia Holch; Michael J Palmer; Michael Brundage Journal: Qual Life Res Date: 2017-02-07 Impact factor: 4.147
Authors: Derek Kyte; Ameeta Retzer; Khaled Ahmed; Thomas Keeley; Jo Armes; Julia M Brown; Lynn Calman; Anna Gavin; Adam W Glaser; Diana M Greenfield; Anne Lanceley; Rachel M Taylor; Galina Velikova; Michael Brundage; Fabio Efficace; Rebecca Mercieca-Bebber; Madeleine T King; Grace Turner; Melanie Calvert Journal: J Natl Cancer Inst Date: 2019-11-01 Impact factor: 13.506
Authors: Rebecca Mercieca-Bebber; Olalekan Lee Aiyegbusi; Madeleine T King; Michael Brundage; Claire Snyder; Melanie Calvert Journal: Qual Life Res Date: 2022-03-26 Impact factor: 3.440